Electro‐Mechanical Dissociation in Chagas Cardiomyopathy: Comparative Analysis of Arrhythmic Burden Beyond LVEF Authors: Luis E Echeverría, Lyda Z Rojas, Angie Yarlady Serrano‐García, Yina T Ariza, Carlos Luengas, Rachel Marcus, Carlos A Morillo, Sergio A Gómez‐Ochoa Published: 2026 ABSTRACT ABSTRACTBackgroundChronic Chagas cardiomyopathy (CCC) exhibits high arrhythmic risk despite preserved systolic function, challenging LVEF‐based stratification.MethodsWe performed a cross‐sectional analysis of 146 heart failure patients (75 CCC, 71 Ischemic Cardiomyopathy [IC]) with comparable age, LVEF, and NT‐proBNP.ResultsCCC patients had a higher arrhythmic burden and NSVT prevalence (RR 4.37, 95% CI 1.67–11.39). NSVT prevalence in CCC was similar regardless of LVEF (p = 0.707). Conventional heart failure severity markers, including worse global and regional strain, were associated with NSVT in IC but not in CCC, where atrial fibrillation (p = 0.002) and ventricular aneurysms (p = 0.033) were the primary associated variables.ConclusionsArrhythmic vulnerability in CCC appears decoupled from LVEF, suggesting that complementary substrate‐based markers may improve risk stratification in this population.Keywords: Chagas cardiomyopathy, non‐sustained ventricular tachycardia, risk stratification, sudden cardiac death, ventricular arrhythmias Introduction Chronic Chagas cardiomyopathy (CCC) is a highly arrhythmogenic condition characterized by extensive fibrosis and neuroautonomic dysfunction [1]. A hallmark of CCC is the occurrence of life‐threatening arrhythmias and sudden cardiac death (SCD) even in the absence of significant left ventricular systolic impairment [2, 3, 4]. Current risk stratification guidelines for implantable cardioverter‐defibrillators (ICD) mention CCC only in passing, and the foundational evidence underpinning these LVEF cutoffs largely originates from landmark trials predominantly enrolling ischemic cardiomyopathy cohorts [5]. Furthermore, randomized trials evaluating the lower efficacy of ICDs to prevent all‐cause mortality in the robust GDMT era are leading to calls to reassess guidance in non‐ischemic cardiomyopathies [6, 7, 8]. In CCC, diffuse patchy fibrosis and conduction scarring may create re‐entrant substrates independent of global pump failure [1]. However, no validated risk models exist for SCD in CCC that adequately address this discrepancy. This study aimed to compare the arrhythmic burden, myocardial remodeling, and cardiac autonomic dysfunction between patients with CCC and IC with similar systolic function (LVEF and global longitudinal strain), and neurohormonal activation (NT‐proBNP levels). Methods Study Design We conducted a cross‐sectional baseline analysis of the Empa‐Chagas prospective cohort at a tertiary center in Colombia. Empa‐Chagas enrolled adults with symptomatic heart failure (HF) of Chagasic or ischemic etiology regardless of the LVEF managed in a specialized heart failure clinic, with participants undergoing a standardized baseline evaluation including detailed clinical history, HF therapy documentation, transthoracic echocardiography with speckle‐tracking analysis, and 24‐h ambulatory ECG monitoring. The main goal of the cohort is to provide insights on the unique pathophysiological and clinical aspects of CCC, as well as to explore differential reverse remodeling during follow‐up. For this baseline analysis we analyzed 146 patients with HF on guideline‐directed medical therapy regardless of their ejection fraction: 75 with CCC and 71 with IC. CCC was diagnosed by two positive serologic assays using distinct techniques, together with a clinical diagnosis of cardiomyopathy/heart failure attributed to Chagas disease by the treating heart failure team (echocardiographic or electrocardiogram abnormalities consistent with CCC, including left anterior fascicular block, right bundle branch block, atrioventricular blocks, ventricular premature complexes, atrial fibrillation or flutter, bradycardia ≤ 50 beats/min, or echocardiographic findings suggestive of myocardial impairment as evaluated by a cardiologist). IC was defined by heart failure attributed to ischemic heart disease, supported by documented prior myocardial infarction and/or obstructive coronary artery disease on coronary angiography in the medical record, and absence of evidence supporting T. cruzi infection (negative serologic assay, which is performed in all patients with HF in the study center). The enrollment strategy ensured cohorts were comparable regarding age, LVEF, and NT‐proBNP (Table 1). This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the local Institutional Review Board (Comité de Ética de Investigación—CEI de la Fundación Cardiovascular de Colombia. Approval number CEI‐2023‐05269). All participants provided written informed consent prior to enrollment. TABLE 1Baseline demographic, clinical, and multimodal characteristics of the study population by etiology.CharacteristicChagasic cardiomyopathy (N = 75)Ischemic cardiomyopathy (N = 71)Total (N = 146) p DemographicsAge (years), median [Q1, Q3]69.0 (62.0, 74.0)65.0 (58.0, 71.0)68.0 (59.2, 73.0)0.096Female, n (%)33 (44.0%)17 (23.9%)50 (34.2%) 0.011 BMI (kg/m2), median [Q1, Q3]23.9 (21.5, 26.4)25.4 (21.8, 27.3)24.6 (21.6, 27.0)0.115Clinical history and vitalsDiabetes, n (%)11 (14.7%)16 (22.5%)27 (18.5%)0.221Hypertension, n (%)33 (44.0%)39 (55.7%)72 (49.7%)0.159Atrial fibrillation, n (%)14 (18.7%)4 (5.6%)18 (12.3%) 0.017 Current smoking, n (%)2 (2.7%)1 (1.4%)3 (2.1%)0.592Stroke, n (%)10 (13.3%)5 (7.1%)15 (10.3%)0.221COPD, n (%)10 (13.3%)3 (4.2%)13 (8.9%)0.053Peripheral arterial disease, n (%)2 (2.7%)3 (4.2%)5 (3.4%)0.605Heart rate (bpm), median [Q1, Q3]62.0 (60.0, 72.5)65.0 (58.5, 70.5)63.0 (60.0, 71.8)0.390Systolic BP (mmHg), median [Q1, Q3]107.0 (93.0, 123.0)103.0 (85.0, 120.5)104.0 (90.2, 121.8)0.107Diastolic BP (mmHg), median [Q1, Q3]59.0 (53.5, 71.5)58.0 (49.5, 70.5)58.0 (51.0, 71.0)0.417NYHA class, n (%)I6 (8.0%)7 (9.9%)13 (8.9%)0.842II63 (84.0%)57 (80.3%)120 (82.2%)III6 (8.0%)7 (9.9%)13 (8.9%)MedicationsAntiarrhythmics20 (26.7%)1 (1.4%)21 (14.4%) < 0.001 ACE inhibitors16 (21.3%)16 (22.5%)32 (21.9%)0.861Beta‐blockers72 (96.0%)67 (94.4%)139 (95.2%)0.644ARBs19 (25.3%)22 (31.0%)41 (28.1%)0.447Diuretics26 (34.7%)12 (16.9%)38 (26.0%) 0.014 Antiplatelets15 (20.0%)66 (93.0%)81 (55.5%) < 0.001 Anticoagulants40 (53.3%)9 (12.7%)49 (33.6%) < 0.001 ARNIs43 (57.3%)32 (45.1%)75 (51.4%)0.138MRAs74 (98.7%)69 (97.2%)143 (97.9%)0.528Implantable devices20 (26.7%)4 (5.6%)24 (16.4%) < 0.001 Biomarkers, median [Q1, Q3]NT‐proBNP (pg/mL)1522.0 (532.8, 3085.7)1033.1 (494.2, 2536.4)1392.7 (502.5, 2905.6)0.823Creatinine (mg/dL)1.1 (0.9, 1.3)1.0 (0.9, 1.2)1.0 (0.9, 1.3)0.495Troponin T (ng/mL)14.6 (8.4, 23.3)12.0 (5.8, 22.5)13.1 (7.4, 23.1)0.624EchocardiographyLVEF (biplane, %), median [Q1, Q3]32.5 (22.0, 44.5)35.0 (28.2, 41.8)35.0 (25.0, 42.5)0.433Reduced LVEF (< 40%), n (%)48 (64.0%)44 (62.0%)92 (63.0%)0.800Global longitudinal strain (%), Median [Q1, Q3]−9.0 (−12.4, −7.0)−10.5 (−12.6, −9.0)−10.0 (−12.5, −7.2)0.107LV mass index (g/m2), median [Q1, Q3]122.0 (98.0, 139.0)93.0 (77.8, 114.5)106.5 (81.0, 133.0) 0.003 LV systolic volume (mL), median [Q1, Q3]88.0 (55.5, 142.0)73.0 (55.0, 97.5)79.5 (55.2, 115.5) 0.042 LV diastolic volume (mL), median [Q1, Q3]138.0 (104.0, 194.0)127.0 (97.5, 159.0)132.0 (100.2, 175.8)0.129LV diameter systole (mm), median [Q1, Q3]50.0 (42.0, 59.0)44.0 (39.0, 52.0)47.0 (41.0, 55.8) 0.015 LV diameter diastole (mm), median [Q1, Q3]60.0 (51.5, 66.5)56.0 (50.0, 61.0)57.0 (51.0, 65.0) 0.037 Left atrial volume index (mL/m2), median [Q1, Q3]52.0 (40.5, 72.5)37.0 (31.5, 50.5)45.0 (34.2, 59.8) < 0.001 Left atrial area (cm2), median [Q1, Q3]25.0 (21.0, 31.0)20.0 (17.0, 25.0)23.0 (19.0, 29.0) < 0.001 Right atrial area (cm2), median [Q1, Q3]19.0 (16.0, 24.0)17.0 (14.0, 19.0)17.0 (15.0, 23.0) 0.012 TAPSE (mm), median [Q1, Q3]17.0 (14.0, 20.0)17.0 (14.0, 20.0)17.0 (14.0, 20.0)0.855TRI (ms), median [Q1, Q3]170.0 (134.5, 198.0)130.0 (101.0, 158.5)149.5 (116.0, 189.0) < 0.001 Mechanical dispersion (PSD), median [Q1, Q3]74.0 (59.5, 107.0)68.0 (53.5, 87.5)71.0 (57.0, 100.8)0.388Diastolic function category, n (%)Normal16 (21.3%)11 (15.5%)27 (18.5%)0.277Grade I dysfunction27 (36.0%)27 (38.0%)54 (37.0%)Grade II dysfunction20 (26.7%)27 (38.0%)47 (32.2%)Grade III dysfunction12 (16.0%)6 (8.5%)18 (12.3%)Aneurysm location (Apical) a 13 (86.7%)10 (100.0%)23 (92.0%)0.229ECG and Holter findingsRBBB, n (%)12 (16.0%)7 (9.9%)19 (13.0%)0.270LBBB, n (%)18 (24.0%)14 (19.7%)32 (21.9%)0.532Left anterior fascicular block, n (%)15 (20.0%)13 (18.3%)28 (19.2%)0.795Left posterior fascicular block, n (%)11 (14.7%)7 (9.9%)18 (12.3%)0.377AV block (1st degree), n (%)6 (8.0%)7 (9.9%)13 (8.9%)0.693AV block (2nd degree), n (%)3 (4.0%)2 (2.8%)5 (3.4%)0.694AV block (3rd degree), n (%)2 (2.7%)3 (4.2%)5 (3.4%)0.605Atrial fibrillation (Holter), n (%)17 (22.7%)3 (4.2%)20 (13.7%) 0.001 Atrial flutter (Holter), n (%)6 (8.0%)1 (1.4%)7 (4.8%)0.062Non‐sustained ventricular tachycardia, n (%)23 (30.7%)5 (7.0%)28 (19.2%) < 0.001 Arrhythmic burden (> 10%), n (%)34 (45.3%)4 (5.6%)38 (26.0%) < 0.001 Total ventricular extrasystoles, median [Q1, Q3]2488.0 (953.0, 5974.5)428.0 (120.5, 1397.0)1043.5 (285.5, 3975.5) < 0.001 Paired ventricular extrasystoles, median [Q1, Q3]86.0 (17.5, 359.0)11.0 (3.0, 44.5)32.5 (6.0, 202.5) < 0.001 Total ventricular runs, median [Q1, Q3]35.0 (6.0, 136.0)3.0 (1.0, 11.0)9.5 (1.0, 61.2) 0.001 Total supraventricular extrasystoles, median [Q1, Q3]817.0 (246.5, 2712.5)138.0 (54.0, 856.0)374.0 (89.8, 1956.8) 0.027 Note: Bold values refer to p‐values < 0.05.Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor‐neprilysin inhibitor; AV, atrioventricular; BMI, body mass index; BP, blood pressure; CCC, chronic Chagas cardiomyopathy; GLS, global longitudinal strain; IC, ischemic cardiomyopathy; LVEF, left ventricular ejection fraction; MLHFQ, Minnesota Living with Heart Failure Questionnaire; MRA, mineralocorticoid receptor antagonist; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; RBBB/LBBB, right/left bundle branch block. a Percentages calculated based on patients with ventricular aneurysm. Data are presented as median [Q1, Q3] or n (%). Baseline demographic, clinical, and multimodal characteristics of the study population by etiology. Note: Bold values refer to p‐values < 0.05. Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor‐neprilysin inhibitor; AV, atrioventricular; BMI, body mass index; BP, blood pressure; CCC, chronic Chagas cardiomyopathy; GLS, global longitudinal strain; IC, ischemic cardiomyopathy; LVEF, left ventricular ejection fraction; MLHFQ, Minnesota Living with Heart Failure Questionnaire; MRA, mineralocorticoid receptor antagonist; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; RBBB/LBBB, right/left bundle branch block. Percentages calculated based on patients with ventricular aneurysm. Data are presented as median [Q1, Q3] or n (%). Assessments All patients underwent transthoracic echocardiography (TTE) with speckle‐tracking and 24‐h Holter monitoring, analyzed by a blinded expert (LEE). TTE assessed cardiac volumes, LVEF (Simpson's biplane), and global longitudinal strain (GLS) using a 17‐segment model. Mechanical dispersion (MD) was calculated as the standard deviation of time to peak negative strain. Holter analysis quantified arrhythmic burden, including premature ventricular complexes (PVCs) and non‐sustained ventricular tachycardia (NSVT), defined as > 3 consecutive ventricular beats (> 100 bpm) lasting < 30 s. We defined high ventricular ectopy burden as premature ventricular complexes (PVCs) comprising ≥ 10% of total beats over 24 h. This cutoff was selected a priori because PVC frequency on Holter is linked to subsequent LVEF decline and incident heart failure in population‐based data, and prior clinical/ablation literature commonly uses high‐burden PVCs (mainly > 10%) when discussing its association with relevant clinical outcomes [9, 10, 11, 12]. Statistical Analysis Continuous variables were tested for normality using the Shapiro–Wilk test and are presented as median and interquartile range (IQR), as most were not normally distributed. Categorical variables are presented as counts and percentages. Differences between the two groups were assessed using the Mann–Whitney U test for continuous variables and the Chi‐squared test or Fisher's exact test, as appropriate, for categorical variables. To explore for differences in relevant arrhythmic parameters between groups, we performed multivariable regression analyses using generalized linear models to account for potential overdispersion. Adjustment covariables included age, sex, left ventricular ejection fraction (LVEF), and plasma NT‐proBNP concentration. A two‐sided p‐value of < 0.05 was considered statistically significant for all analyses. Statistical analyses were performed using R software, version 4.2.0 (R Foundation for Statistical Computing, Vienna, Austria). Results Overall 146 patients were included in this analysis; 75 patients with CCC and 71 with IC. Both cohorts were comparable in terms of age (median 69.0 vs. 65.0 years, p = 0.096), left ventricular ejection fraction (LVEF) (median 32.5% vs. 35.0%, p = 0.433), and levels of NT‐proBNP (median 1522.0 vs. 992.8 pg/mL, p = 0.725) (Table 1). Moreover, while global strain was similar between groups, regional analysis revealed distinct patterns. CCC patients showed significantly worse strain in basal inferolateral and inferior segments (p < 0.005), consistent with typical fibrosis distribution in this cardiomyopathy, whereas IC defects followed coronary territories (Figure 1). Comparison of segmental strain (bull's‐eye plot) between chronic Chagas cardiomyopathy and ischemic cardiomyopathy. Values within each segment represent mean strain (%) ± standard deviation. Despite similar systolic function, CCC patients demonstrated a markedly more malignant arrhythmic phenotype. The arrhythmic burden was higher, with a larger proportion of patients with > 10% of PVCs in 24 h (45.3% vs. 5.6%, p < 0.001). The burden of supraventricular arrhythmias was also higher in the CCC cohort (Table 1). CCC patients also exhibited significant autonomic derangement, indicated by lower heart rate variability indices (Table 1). The prevalence of NSVT was significantly higher in CCC compared to IC (30.7% vs. 7.0%; multivariable RR 4.37, 95% CI 1.67–11.39, p = 0.002). Crucially, the relationship between arrhythmia and LVEF diverged by etiology (Figure 2). In CCC, NSVT prevalence was numerically higher among patients with LVEF ≥ 40% than among those with LVEF < 40% (33.3% vs. 29.2%, p = 0.707), and mean LVEF was comparable between NSVT and non‐NSVT groups (35.0% vs. 32.3%, p = 0.817) (Table 2). Conversely, in IC, NSVT prevalence increased numerically with worsening systolic dysfunction (3.7% in LVEF ≥ 40% vs. 9.1% in LVEF < 40%), and patients with NSVT had lower LVEF than those without (25.0% vs. 35.5%, p = 0.053), although this difference was not statistically significant (Figure 2 and Table 2). Furthermore, ventricular aneurysms were strongly associated with NSVT in CCC (34.8% vs. 13.5%, p = 0.033). In contrast, NSVT in IC was associated with traditional severity markers such as larger ventricular volumes and lower LVEF (Table 2). Finally, in IC NSVT was accompanied by worse GLS (−6.4% vs. −10.7%, p = 0.007), with no differences observed in CCC (−8.0% vs. −9.0%, p = 0.781). Similarly, regional strain did not differ markedly across NSVT strata in CCC, whereas in IC patients with NSVT the mid inferior (−6.0% vs. −11.0%, p = 0.007) and inferoseptal (−5.0% vs. −10.0%, p = 0.015) segments showed worse strain values (Figure 3). Arrhythmic burden and NSVT prevalence by etiology. (A) Violin plots demonstrating the distribution of total ventricular premature beats (VPBs) and VPB couplets, and a bar chart showing the prevalence of ectopic beats ≥ 10% of total heartbeats. (B) Bar chart illustrating the prevalence of non‐sustained ventricular tachycardia (NSVT) stratified by LVEF category (≥ 40% vs. < 40%) for both etiologies. TABLE 2Baseline characteristics of patients with chronic Chagas cardiomyopathy and ischemic cardiomyopathy, stratified by NSVT.CharacteristicChronic Chagas cardiomyopathyIschemic cardiomyopathyNo NSVT (N = 52)NSVT (N = 23) p No NSVT (N = 66)NSVT (N = 5) p Demographics and vitalsAge (years), median [Q1, Q3]70.0 (63.8, 75.2)62.0 (58.0, 72.0)0.07565.5 (58.0, 71.0)63.0 (60.0, 71.0)0.870Female, n (%)21 (40.4%)12 (52.2%)0.34316 (24.2%)1 (20.0%)0.830BMI (kg/m2), median [Q1, Q3]23.9 (21.2, 26.2)24.0 (21.7, 26.8)0.80525.4 (21.7, 27.3)25.5 (25.4, 27.5)0.201Heart rate (bpm), Median [Q1, Q3]63.0 (60.0, 75.2)60.0 (59.0, 70.5)0.20264.5 (58.0, 71.8)65.0 (60.0, 66.0)0.771Systolic BP (mmHg), Median [Q1, Q3]110.0 (94.8, 125.5)98.0 (90.0, 111.0)0.113101.0 (85.0, 118.0)120.0 (93.0, 122.0)0.616Diastolic BP (mmHg), Median [Q1, Q3]60.5 (54.0, 74.5)57.0 (48.5, 63.5)0.14356.0 (48.2, 69.8)61.0 (58.0, 80.0)0.220Comorbidities and lifestyle, n (%)Diabetes8 (15.4%)3 (13.0%)0.79214 (21.2%)2 (40.0%)0.332Hypertension26 (50.0%)7 (30.4%)0.11537 (56.9%)2 (40.0%)0.463Atrial fibrillation5 (9.6%)9 (39.1%) 0.002 3 (4.5%)1 (20.0%)0.148Current smoking1 (1.9%)1 (4.3%)0.5481 (1.5%)0 (0.0%)0.782Current alcohol use4 (7.7%)0 (0.0%)0.1724 (6.1%)0 (0.0%)0.571Regular physical activity16 (30.8%)11 (47.8%)0.15636 (55.4%)3 (60.0%)0.841Stroke7 (13.5%)3 (13.0%)0.9615 (7.7%)0 (0.0%)0.520COPD8 (15.4%)2 (8.7%)0.4322 (3.0%)1 (20.0%)0.069Peripheral arterial disease2 (3.8%)0 (0.0%)0.3403 (4.5%)0 (0.0%)0.626NYHA class, n (%)I3 (5.8%)3 (13.0%)0.1547 (10.6%)0 (0.0%)0.056II43 (82.7%)20 (87.0%)54 (81.8%)3 (60.0%)III6 (11.5%)0 (0.0%)5 (7.6%)2 (40.0%)MLHFQ total score, median [Q1, Q3]36.0 (20.8, 54.2)32.0 (24.0, 38.0)0.37328.5 (17.0, 42.0)37.0 (21.0, 70.0)0.118Implantable device12 (23.1%)8 (34.8%)0.2901 (1.5%)3 (60.0%) < 0.001 Biomarkers, median [Q1, Q3]NT‐proBNP (pg/mL)1640.0 (665.0, 3687.6)1454.0 (440.1, 2660.2)0.097993.4 (471.7, 2391.6)1033.1 (758.0, 6883.5) 0.003 Creatinine (mg/dL)1.1 (0.8, 1.3)0.9 (0.9, 1.2)0.2901.0 (0.9, 1.2)0.8 (0.8, 1.0)0.351EchocardiographyLV structure and functionLVEF (biplane, %)32.2 (23.9, 42.6)35.0 (19.0, 45.0)0.81735.5 (30.0, 42.0)25.0 (18.0, 33.0)0.053Reduced LVEF (< 40%), n (%)34 (65.4%)14 (60.9%)0.70740 (60.6%)4 (80.0%)0.389Global longitudinal strain (%)−9.0 (−12.4, −7.0)−8.0 (−12.7, −7.0)0.781−10.7 (−12.6, −9.1)−6.4 (−7.0, −4.0) 0.007 LV systolic volume (mL)82.5 (56.8, 134.8)105.0 (53.5, 148.0)0.78270.5 (53.2, 94.8)111.0 (92.0, 151.0) 0.004 LV diastolic volume (mL)132.0 (101.8, 194.0)150.0 (123.0, 194.5)0.793125.5 (97.0, 158.0)156.0 (146.0, 202.0) 0.013 LV mass index (g/m2)120.5 (99.0, 136.0)122.0 (86.5, 145.0)0.40192.5 (76.9, 112.5)149.0 (86.4, 188.0) 0.020 LV diameter systole (mm)50.5 (42.0, 57.2)50.0 (42.5, 60.5)0.75243.0 (39.0, 50.0)54.0 (49.0, 66.0) 0.030 LV diameter diastole (mm)60.0 (52.0, 66.0)57.0 (51.0, 68.0)0.77556.0 (50.0, 60.8)62.0 (57.0, 75.0) 0.036 Mechanical dispersion (PSD)74.0 (58.5, 108.5)81.0 (63.5, 97.0)0.90967.5 (53.2, 84.8)131.0 (56.0, 134.0)0.091Left atrial volume index (mL/m2)53.5 (38.8, 75.8)51.0 (43.0, 63.0)0.78836.0 (31.0, 48.0)53.0 (47.0, 68.0) < 0.001 Left atrial area (cm2)25.5 (20.0, 31.2)25.0 (22.5, 31.0)0.99320.0 (17.0, 24.8)28.0 (24.0, 30.0) 0.003 Right atrial area (cm2)19.0 (16.0, 24.5)19.0 (16.5, 22.5)0.66516.0 (14.0, 19.0)38.0 (23.0, 38.0) < 0.001 TAPSE (mm)17.0 (13.0, 20.0)17.0 (16.0, 21.0)0.14317.0 (15.0, 20.0)13.0 (11.0, 15.0)0.123Diastolic function, n (%)Normal10 (19.2%)6 (26.1%)0.8729 (13.6%)2 (40.0%)0.278Grade I dysfunction19 (36.5%)8 (34.8%)26 (39.4%)1 (20.0%)Grade II dysfunction15 (28.8%)5 (21.7%)26 (39.4%)1 (20.0%)Grade III dysfunction8 (15.4%)4 (17.4%)5 (7.6%)1 (20.0%)ECG & Holter findingsRBBB, n (%)6 (11.5%)6 (26.1%)0.1137 (10.6%)0 (0.0%)0.443LBBB, n (%)10 (19.2%)8 (34.8%)0.14612 (18.2%)2 (40.0%)0.237Left anterior fascicular block, n (%)10 (19.2%)5 (21.7%)0.80213 (19.7%)0 (0.0%)0.272Left posterior fascicular block, n (%)8 (15.4%)3 (13.0%)0.7927 (10.6%)0 (0.0%)0.443AV block (1st degree), n (%)6 (11.5%)0 (0.0%)0.0897 (10.6%)0 (0.0%)0.443AV block (2nd degree), n (%)2 (3.8%)1 (4.3%)0.9192 (3.0%)0 (0.0%)0.693AV block (3rd degree), n (%)1 (1.9%)1 (4.3%)0.5483 (4.5%)0 (0.0%)0.626Atrial fibrillation (Holter), n (%)14 (26.9%)3 (13.0%)0.1862 (3.0%)1 (20.0%)0.069Atrial flutter (Holter), n (%)2 (3.8%)4 (17.4%) 0.046 1 (1.5%)0 (0.0%)0.782Arrhythmic burden > 10%, n (%)16 (30.8%)18 (78.3%) < 0.001 2 (3.0%)2 (40.0%) < 0.001 Total ventricular extrasystoles1209.0 (634.0, 3212.0)8739.0 (4656.5, 13416.5) < 0.001 375.5 (91.2, 921.8)3067.0 (2906.0, 4000.0) < 0.001 Paired ventricular extrasystoles35.5 (9.0, 114.8)398.0 (250.0, 783.5) < 0.001 9.0 (3.0, 35.0)213.0 (174.0, 261.0) < 0.001 Total ventricular runs18.0 (3.0, 38.2)316.0 (168.0, 475.5) < 0.001 2.0 (0.2, 7.8)134.0 (125.0, 157.0) < 0.001 Total supraventricular extrasystoles425.0 (147.0, 1670.2)2682.0 (1717.5, 3329.5)0.065128.5 (52.2, 744.8)1967.0 (176.0, 5218.0)0.143Paired supraventricular extrasystoles15.5 (6.2, 65.0)207.0 (63.0, 419.0)0.23820.0 (7.0, 66.0)477.0 (477.0, 477.0)0.138Total supraventricular runs6.0 (1.0, 38.8)54.0 (22.5, 159.2)0.6161.0 (0.0, 3.8)2.0 (2.0, 154.0)0.408Long supraventricular runs110.0 (94.0, 128.5)86.0 (79.8, 90.8)0.536119.0 (90.5, 133.8)90.0 (90.0, 90.0)0.652 Note: Bold values refer to p‐values < 0.05.Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor‐neprilysin inhibitor; AV, atrioventricular; BMI, body mass index; BP, blood pressure; CCC, chronic Chagas cardiomyopathy; GLS, global longitudinal strain; IC, ischemic cardiomyopathy; LVEF, left ventricular ejection fraction; MLHFQ, Minnesota Living with Heart Failure Questionnaire; MRA, mineralocorticoid receptor antagonist; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; RBBB/LBBB, right/left bundle branch block. Baseline characteristics of patients with chronic Chagas cardiomyopathy and ischemic cardiomyopathy, stratified by NSVT. Note: Bold values refer to p‐values < 0.05. Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor‐neprilysin inhibitor; AV, atrioventricular; BMI, body mass index; BP, blood pressure; CCC, chronic Chagas cardiomyopathy; GLS, global longitudinal strain; IC, ischemic cardiomyopathy; LVEF, left ventricular ejection fraction; MLHFQ, Minnesota Living with Heart Failure Questionnaire; MRA, mineralocorticoid receptor antagonist; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; RBBB/LBBB, right/left bundle branch block. Comparison of left ventricular segmental strain patterns in cardiomyopathy patients stratified by the presence of non‐sustained ventricular tachycardia (NSVT). Bull's‐eye polar maps depict the 17‐segment model of the left ventricle for patients with (A) Chagasic cardiomyopathy and (B) Ischemic cardiomyopathy. Values within each segment represent mean strain (%) ± standard deviation. Discussion In this baseline analysis of the Empa‐Chagas cohort, patients with CCC presented a significantly more malignant phenotype than IC patients despite comparable age, LVEF, and neurohormonal activation, suggesting a dissociation between global systolic function and arrhythmic risk in CCC. Guidelines rooted in ischemic data assume that arrhythmic risk correlates linearly with systolic ventricular dysfunction [5]. The dissociation between global systolic function and arrhythmic burden in CCC can be explained by its unique pathophysiology, as it is characterized by segmental and patchy myocardial fibrosis, inflammation‐related injury, and autonomic imbalance that can promote heterogeneous conduction and dispersion of refractoriness, creating a substrate for re‐entry even before advanced global pump failure [1]. Ventricular aneurysms, a classic CCC phenotype, further concentrate scar‐related circuits and provide anatomical corridors that facilitate ventricular tachyarrhythmias [13]. Consistent with this paradigm, myocardial fibrosis burden by cardiac magnetic resonance (CMR) has been associated with adverse outcomes in CCC, and electrophysiologic studies support a distinct VT substrate in CCC, often involving inferolateral regions and frequently requiring epicardial mapping/ablation strategies [14, 15]. Finally, deformation heterogeneity captured by strain‐based indices (including mechanical dispersion) has been associated with ventricular arrhythmias in structural heart disease and may represent a functional correlate of scar heterogeneity in CCC. Notably, Azevedo et al. [16, 17] showed in 77 CCC patients that mechanical dispersion was the independent echocardiographic correlate of NSVT, while GLS lost independence in multivariable analysis. In line with this, our segmental strain analysis (Figure 3) showed broadly overlapping regional strain magnitudes between CCC patients with and without NSVT, in contrast to the ischemic cohort. Of note, the absence of a clear strain gradient in the basal‐inferolateral segments—the classical site of CCC aneurysms and a recognized arrhythmic substrate—likely reflects three factors: that segment‐level averaging dilutes focal scar–border‐zone signals; that arrhythmogenicity in CCC also arises from apical aneurysms, septal involvement, and patchy noncontiguous fibrosis beyond the inferolateral wall; and that segmental strain correlates only modestly with CMR‐defined fibrosis at the segment level [13, 18, 19]. Together, these factors support the view that arrhythmic vulnerability in CCC is not exclusively related to systolic function. Consequently, LVEF‐based thresholds alone may incompletely capture arrhythmic vulnerability in CCC, as approximately one‐third of patients with LVEF ≥ 40% in our cohort exhibited high‐risk arrhythmic features (NSVT and significant ventricular ectopy). There is a growing understanding that there are a subset of arrhythmogenic cardiomyopathies for which heightened concern for SCD is appropriate (sarcoid, laminopathy), and given CCC's distinct pathophysiology, it should be considered a high‐risk disease in this context [20]. It is important to contextualize our findings within the existing prognostic evidence in CCC. Sarabanda and Marin‐Neto demonstrated in a cohort of 56 chagasic patients with CCC and ventricular tachycardia that LVEF < 40% was the only independent predictor of both all‐cause mortality (HR 12.22, 95% CI 3.46–43.17) and sudden cardiac death (HR 6.58, 95% CI 1.74–24.88), underscoring that systolic dysfunction remains a powerful prognostic marker when hard clinical endpoints are considered [21]. Our study, being cross‐sectional in design, assessed arrhythmic burden surrogates (NSVT, PVC density) rather than incident sustained VT/VF or sudden death, and therefore does not directly challenge these findings. Rather, the observation that NSVT prevalence was comparable across LVEF strata in CCC, while tracking with systolic impairment in IC, suggests that arrhythmic substrate may be partially independent of global pump function in this etiology. Whether these surrogate markers translate into differential risk of sustained arrhythmias and SCD requires prospective validation, which is the focus of the ongoing Empa‐Chagas follow‐up. Beyond the markers assessed in this study, myocardial fibrosis burden by CMR has the potential to significantly improve discrimination of patients at risk of SCD in CCC and may serve as a substrate marker to complement rhythm surveillance. These markers require validation in future prospective studies in order to contribute to the development of novel LVEF‐independent criteria for ICD indication in CCC patients, which have the potential to significantly mitigate the burden of SCD in this neglected population. As an observational single‐center study, unmeasured confounding and limited generalizability are inherent limitations. The modest sample sizes limited statistical power for some analyses. Furthermore, NSVT detection is limited to 24‐h monitoring; longer surveillance might reveal additional events. Finally, because this report is a baseline cross‐sectional analysis, we do not present comparative rates of sustained VT/VF or sudden death between etiologies here; these clinically definitive outcomes are the focus of the cohort's ongoing prospective follow‐up. Funding The present study received funding from Boehringer Ingelheim (ECR_2024_00004180) as part of an Investigator‐Initiated Study (IIS). This was a collaborative research study where BI was involved in the design of the study but was not the regulatory sponsor. BI was given the opportunity to review the manuscript for medical and scientific accuracy as it relates to BI substances, as well as intellectual property considerations. Ethics Statement The study was approved by the local Institutional Review Board (Comité de Ética de Investigación—CEI de la Fundación Cardiovascular de Colombia. Approval number CEI‐2023‐05269). Consent All patients provided written informed consent to participate in the study. Conflicts of Interest S.A.G.‐O., L.Z.R., and L.E.E. received research funding from Boehringer Ingelheim S.A. for the development of the EMPA‐Chagas study. The author(s) meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). Echeverría L. E., Rojas L. Z., Serrano‐García A. Y., et al., “Electro‐Mechanical Dissociation in Chagas Cardiomyopathy: Comparative Analysis of Arrhythmic Burden Beyond LVEF ,” Journal of Arrhythmia 42, no. 3 (2026): e70365, 10.1002/joa3.70365. Prior Dissemination: Part of the preliminary baseline EMPA‐Chagas arrhythmic phenotyping (24‐h Holter comparisons of ventricular ectopy and NSVT between CCC and IC) was previously described in a Letter to the Editor (Cardiovasc Drugs Ther. 2024;38:203–205; doi:10.1007/s10557‐023‐07510‐8). The present manuscript reports the full baseline analysis with expanded methods and additional deformation and multivariable analyses not included in the prior publication. Contributor Information Luis E. Echeverría, Email: luisecheverria@fcv.org. Sergio A. Gómez‐Ochoa, Email: sergiogomezochoa@fcv.org. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.